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Abstract
Background
Sex hormones play a role in gastric cancer and colorectal cancer etiology, however, epide-
miological evidence is inconsistent. This study examines the influence of menstrual and
reproductive factors over the risk of both tumors.
Methods
In this case-control study 128 women with gastric cancer and 1293 controls, as well as 562
female and colorectal cancer cases and 1605 controls were recruited in 9 and 11 Spanish
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association with gastric, colon and rectal cancer was assessed using logistic and multino-
mial mixed regression models.
Results
Our results show an inverse association of age at first birth with gastric cancer risk (five-
year trend: OR = 0.69; p-value = 0.006). Ever users of hormonal contraception presented a
decreased risk of gastric (OR = 0.42; 95%CI = 0.26–0.69), colon (OR = 0.64; 95%CI =
0.48–0.86) and rectal cancer (OR = 0.61; 95%CI = 0.43–0.88). Postmenopausal women
who used hormone replacement therapy showed a decreased risk of colon and rectal
tumors. A significant interaction of educational level with parity and months of first child lac-
tation was also observed.
Conclusion
These findings suggest a protective role of exogenous hormones in gastric and colorectal
cancer risk. The role of endogenous hormones remains unclear.
Introduction
Colorectal cancer (CRC) in Spain, with an estimated 16071 new cases in 2014 [1], represents
the secondmost common tumor in women and the second leading cause of death, accounting
for 15.3% of all female cancer-related deaths in 2013 [2]. In Spain, as in other developed coun-
tries [3], there has been an increase in incidence due to this type of cancer, slightly attenuated
around 1995 [4]. However, mortality rates have reached a plateau since the beginning of this
century [5].
Gastric cancer (GC) in Spanish women occupies the tenth position in incidence, with an
adjusted rate of 7.5 cases per 100,000 estimated for 2012 [6]. In terms of mortality, the rate esti-
mated for this same year was 4.8 per 100,000, accounting for 5.3% of all female cancer-related
deaths in 2013 [2]. The small difference between the incidence and mortality rates is due to the
low survival recorded for this tumor, which is estimated in Spain to be 26.0% at 5 years [1].
Hormonal factors may play a role in the etiology of both tumors: incidence is approximately
twofold higher among males than among females [6], even though differential exposure to
established risk factors cannot totally explain these differences. On the other hand, it has been
suggested that estrogens may offer protection against the development of both tumors, and this
protective effect seems to be modulated through estrogen receptors (ER) identified in non-
cancerous and cancerous gastric [7] and colonic tissue [8, 9]. Recent studies indicate that the
protection conferred to CRC risk could be limited to certainmolecular tumor subtypes [8] and
to exogenous estrogens exposure [9, 10]. On the contrary, while some studies have observed
lower GC risk associated with the exposure to estrogens of both ovarian and exogenous origin
[11], other authors have detected this association with endogenous estrogen exposure only
[12].
The role of menstrual and reproductive factors in the etiology of GC, and mainly CRC, has
drawn interest in the literature, but findings are not consistent, especially in the case of GC
where most studies have been limited by small number of cases. This study sought to investi-
gate the influence of menstrual and reproductive factors on female GC and CRC risk in a large
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population-based case control study in Spain. We also assessed if these associations differ by
specific CRC subsite. Finally, taking into account that reproductive patterns and the use of hor-
monal compounds are strongly influenced by womens’ educational level [13] and that highly
educated women tend to have healthier life-styles [14, 15], we evaluated the influence of repro-
ductive factors separately in women with high and low educational background.
Materials and Methods
Study population
Multicase-control Spain study (MCC-Spain, www.mccspain.org) [16], with population con-
trols and incident cases was carried out between September 2008 and December 2013 to inves-
tigate the influence of environmental factors and their interaction with genetic factors in highly
prevalent tumors or with peculiar epidemiological characteristics in Spain. Cases of breast,
prostate, gastric, colorectal tumors and chronic lymphocytic leukemias were recruited from 23
hospitals in 12 Spanish provinces. Inclusion criteria required that participants should have
resided for at least 6 months in the study areas, had to be aged 20–85 and had to be mentally
qualified to answer the questionnaire. A group of controls, common for the five types of
tumors, was randomly selected from the administrative records of a number of primary care
health centers within the catchment areas of the hospitals where cases were recruited.We
made an initial estimate of the age-sex distribution that cases–all combined- would have in
each region, according to the tumors they recruited and to the cancer incidence rates from
Spanish cancer registries.We applied these estimates to predefine the age-sex distribution of
our population-based controls, which were selected randomly from the general practitioner
lists of each hospital catchment area. When the recruitment of cases ended, we compared again
the age- sex- distribution of cases and controls and recruited new participants if needed in an
attempt to ensure that each case had at least one control of the same 5-year age interval and sex
in each region. Controls were initially contacted via telephone and those who agreed to partici-
pate in the study were scheduled for a personal interview. Cases of GC were recruited in
Madrid, Barcelona, León, Navarra, Cantabria, Asturias, Huelva, Valencia and Granada. CRC
cases were also recruited in Guipúzcoa and Murcia. Our research personnel actively searched
for new cases, through regular visits to the collaborating hospital departments (gastroenterol-
ogy, oncology, general surgery, radiotherapy and pathology) and reviewed the hospital admis-
sion registries weekly.
For the present study we recruited a total of 151 histologically-confirmedfemale GC cases
(codes C16:Malignant neoplasm of stomach and D00.2:Carcinoma in situ of stomach, according
to the 10th revision of the International Statistical Classification of Diseases), and 775 female
CRC cases (codes C18:Malignant neoplasm of colon, C19:Malignant neoplasm of rectosigmoid
junction, C20:Malignant neoplasm of rectum, D01.0:Carcinoma in situ of colon, D01.1:Carci-
noma in situ of rectosigmoid junction and D01.2:Carcinoma in situ of rectum) with no prior his-
tory of the disease and diagnosedwithin the recruitment period. Those controls with a history
of GC or CRC were excluded, as well as those who resided in provinces that had not recruited
these tumors and those that were more than five years younger than the youngest case included
in each region. A total of 1548 and 1932 female controls were included for the GC and CRC
analyses, respectively. Flow charts displaying the selection process of CRC cases and controls
and GC cases and control are shown in Fig 1 and Fig 2 respectively.
Ethical approval
The protocol of MCC-Spain was approved by Ethics Committees of the participating institu-
tions: Comité Ético de Investigación Clínica (CEIC) del Instituto Municipal de Asistencia
Obstetric History and Gastric / Colorectal Tumors
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Sanitaria de Barcelona; CEIC del Hospital Universitario de Bellvitge; CEIC de Navarra; CEIC
del Hospital Universitario La Paz; CEIC del Hospital Universitario Ramón y Cajal; CEIC de
Cantabria; CEIC de la DirecciónGeneral de Salud Pública y Centro Superior de Investigación
en Salud Pública; CEIC del Hospital General Universitario Jose Mª Morales Meseguer; Comité
de Ética de la Investigación de la Provincia de Huelva; CEIC de León; Comité Ético de Investi-
gación del Principado de Asturias; Comité de Ética de la Investigación Biomédica Provincial de
Granada; Comité de Ética en Investigación Humana de la Universidad de Granada; Comité
Ético de Investigación de la Comunidad Autónoma del País Vasco. All participants were
informed about the study objectives and signed an informed consent. Confidentiality of data is
secured removing personal identifiers in the datasets. The database was registered in the Span-
ish Agency for Data Protection, number 2102672171.
Data collection
Exposure information was collected by trained interviewers through face-to-face interviews
using a structured electronic questionnaire, including detailed information on demographic
factors, occupation, personal and family history, lifestyle and diet [17]. Menstrual factors
Fig 1. Flow chart displaying the selection process of colorectal cancer cases and controls. MCC-Spain study 2008–2013.
doi:10.1371/journal.pone.0164620.g001
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gathered by the questionnaire included age at menarche, regularity of the menstrual cycle,
menopausal status, age and cause of menopause, use of hormonal contraceptives and hormone
replacement therapy. Regarding reproductive history, the questionnaire collected information
on fertility problems and their treatment, number of miscarriages, number of children, new-
borns' sex, year of birth, gestational age and duration of maternal lactation.
Statistical analyses
Descriptive analyses of participants’ characteristics were done for GC, colon cancer (CC) and
rectal cancer (RC) cases and controls. We used absolute figures and percentages to describe cat-
egorical variables, and means and standard deviations to describe continuous variables. Signifi-
cant differences between cases and controls were tested using Pearson chi-square and Student's
t-test for categorical and continuous variables respectively.
The association of menstrual and reproductive variables with GC, CC and RC was assessed
using logistic mixed regression models, including the province as a random effect term to
account for unexplained heterogeneity associated with province, such as distribution of
unmeasured potential risk factors or differences between interviewers.Models were adjusted
Fig 2. Flow chart displaying the selection process of gastric cancer cases and controls. MCC-Spain study 2008–2013.
doi:10.1371/journal.pone.0164620.g002
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for age, educational level, bodymass index (BMI) one year prior to the interview, tobacco con-
sumption, family history of the studied cancer, hormone replacement therapy use and hor-
monal contraception use.We also conducted an additional analysis in CRC cases and controls
stratifying by educational level, not done for GC due to the low number of cases. Finally, a sen-
sitivity analysis was done additionally adjusting for calorie intake, red meat, processedmeat,
fruits, vegetables and alcohol consumption in those participants who fulfilled the food fre-
quency questionnaire (Supporting Information).
CRC patients were classified according to tumor subsite: CC and RC (two cases were of
unspecified subsite). Since our response variable has three categories (0 = controls, 1 = CC
cases and 2 = RC cases), we fitted multinomial logistic regression models to evaluate the associ-
ation of menstrual and reproductive factors with the above-mentioned CRC subsites. These
models were adjusted by the same set of variables described above, including the province as a
random effect term. Heterogeneity of effects was tested using a Wald test to compare the coeffi-
cients obtained for the different CRC subsites. Data were analyzed using STATA/MP 13.1
software.
Results
Response rates were 53.8% for healthy female controls, 62.1% for female CRC cases and 55.7%
for female GC cases. Results presented in this manuscript are based on women with no missing
values in any of the selected confounders (73% of CRC cases, 85% of GC cases and 83% of con-
trols). We included 562 CRC cases (364 colon cases and 196 rectal cases) and 1605 controls, as
well as 128 GC cases and 1293 controls. Table 1 shows the main characteristics of these
women. In general, gastric, colon and rectal cases were older and had higher BMI than controls.
They also smoked less, had lower educational level, had a delayed menarche, had more chil-
dren, had their first child at a younger age, had longer breastfeeding periods and reported to
use less hormone replacement therapy and hormonal contraception than controls.
Table 2 shows the association betweenGC, CC and RC risk and menstrual and reproductive
factors. Age at first birth displayed an inverse association with GC, decreasing the risk by 31%
for every five years increase in age at first birth (P = 0.006) (>29 years vs.<25: OR = 0.52; 95%
CI = 0.28–0.97). This result remained significant even after adjustment for number of children
(five-year trend: OR = 0.71; P = 0.014) or additionally adjusting for calorie intake, red meat,
processedmeat, fruits, vegetables and alcohol consumption (five-year trend: OR = 0.71;
P = 0.046) (S1 Table). Women who ever used hormonal contraception showed a decreased gas-
tric (OR = 0.42; 95%CI = 0.26–0.69), colon (OR = 0.64; 95%CI = 0.48–0.86), and rectal
(OR = 0.61; 95%CI = 0.43–0.88) cancer risk, results that are confirmed after adjustment for
calorie intake, red meat, processedmeat, fruits, vegetables and alcohol consumption. The pro-
tection conferred by hormonal contraception use was stronger for those who used it more than
5 years for all cancer types (OR for GC = 0.26; 95%CI = 0.10–0.67; OR for CC = 0.59; 95%
CI = 0.38–0.92; OR for RC = 0.53; 95%CI = 0.30–0.95). Finally, postmenopausal women
who ever used hormone replacement therapy showed a decreasedCC risk (OR = 0.44; 95%
CI = 0.24–0.78) and almost significant decreasedRC risk (OR = 0.51; 95%CI = 0.24–1.07). No
significant differences were detected between colon and rectal tumors in any of the variables
analyzed. Also, no significant associations were observedbetweenGC, CC and RC risk and
other menstrual and reproductive variables (history of miscarriages, age at menopause, fertility
time, fertility time without children, time since last child, time since menopause, and each
woman's cumulative lifetime lactation) (data not shown).
Table 3 presents the results of these associations with CRC risk stratified by educational
background. Number of children and months of lactation displayed different effects in women
Obstetric History and Gastric / Colorectal Tumors
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Table 1. Socio-demographic, menstrual and reproductive characteristics in gastric and colorectal cancer cases and controls.
GASTRIC CANCER COLORECTAL CANCER
Controls Cases Controls Colon cases Rectal cases
(N = 1293) (N = 128) (N = 1605) (N = 364) (N = 196)
N (%) N (%) p-val N (%) N (%) p-val N (%) p-val
Age, mean(SD) 59.5 (12.6) 65.0 (14.2) <0.001 58.9 (12.5) 65.5 (11.4) <0.001 64.3 (11.8) <0.001
Educational level <0.001 <0.001 <0.001
Less than primary school 197 (15%) 52 (41%) 259 (16%) 108 (30%) 65 (33%)
Primary school completed 422 (33%) 47 (37%) 490 (31%) 140 (38%) 74 (38%)
Secondary school 392 (30%) 24 (19%) 495 (31%) 73 (20%) 35 (18%)
University graduate 282 (22%) 5 (4%) 361 (22%) 43 (12%) 22 (11%)
BMI 0.003 <0.001 0.045
<20 Kg/m2 91 (7%) 5 (4%) 111 (7%) 15 (4%) 13 (7%)
20–24 Kg/m2 542 (42%) 36 (28%) 681 (42%) 116 (32%) 64 (33%)
25–29 Kg/m2 409 (32%) 50 (39%) 506 (32%) 139 (38%) 78 (40%)
>29 Kg/m2 251 (19%) 37 (29%) 307 (19%) 94 (26%) 41 (21%)
Smoking 0.001 <0.001 0.004
Never smoker 778 (60%) 97 (76%) 934 (58%) 257 (71%) 135 (69%)
Former smoker > 1.5 years 257 (20%) 10 (8%) 332 (21%) 56 (15%) 38 (19%)
Smoker or former smoker <1.5 years 258 (20%) 21 (16%) 339 (21%) 51 (14%) 23 (12%)
Family history colorectal/gastric cancer <0.001 <0.001 0.005
None 1160 (90%) 90 (70%) 1397 (87%) 283 (78%) 160 (82%)
Second degree only 77 (6%) 9 (7%) 67 (4%) 15 (4%) 7 (4%)
1 first degree 53 (4%) 20 (16%) 129 (8%) 55 (15%) 23 (12%)
>1 first degree 3 (0%) 9 (7%) 12 (1%) 11 (3%) 6 (3%)
Age at menarche, mean(SD) 12.8 (1.7) 13.2 (2.0) 0.018 12.8 (1.6) 13.0 (1.7) 0.024 13.2 (1.6) 0.006
Number of children 0.006 0.001 0.047
None 235 (18%) 22 (17%) 278 (17%) 43 (12%) 27 (14%)
1–2 716 (55%) 55 (43%) 902 (56%) 190 (52%) 99 (51%)
3–4 279 (22%) 39 (30%) 350 (22%) 103 (28%) 58 (30%)
>4 61 (5%) 12 (9%) 72 (4%) 28 (8%) 12 (6%)
Age at first birth, mean(SD) 26.7 (4.8) 24.8 (4.7) <0.001 26.8 (4.8) 26.2 (4.5) 0.040 26 (5.2) 0.051
Lactation first child (months), mean(SD) 4.5 (5.7) 5.5 (5.8) 0.113 4.4 (5.6) 5.4 (6.1) 0.008 5.6 (6.1) 0.020
History of miscarriages 0.768 0.013 0.597
None 985 (76%) 99 (77%) 1231 (77%) 301 (83%) 147 (75%)
One or more 308 (24%) 29 (23%) 374 (23%) 63 (17%) 49 (25%)
Menopausal status 0.001 <0.001 <0.001
Premenopausal 340 (26%) 17 (13%) 456 (28%) 39 (11%) 29 (15%)
Posmenopausal 953 (74%) 111 (87%) 1149 (72%) 325 (89%) 167 (85%)
Hormonal contraception use <0.001 <0.001 <0.001
Never 668 (52%) 101 (79%) 809 (50%) 254 (70%) 135 (69%)
Ever 625 (48%) 27 (21%) 796 (50%) 110 (30%) 61 (31%)
Postmenopausal women
Hormone therapy use 0.121 <0.001 0.016
Never 858 (90%) 105 (95%) 1025 (89%) 311 (96%) 159 (95%)
Ever 95 (10%) 6 (5%) 124 (11%) 14 (4%) 8 (5%)
Age at menopause, mean(SD) 48.4 (5.3) 47.9 (5.6) 0.397 48.6 (5.3) 48.7 (5.2) 0.667 48.7 (5.0) 0.663
Fertility time (years), mean(SD) 35.5 (5.4) 34.7 (5.7) 0.183 35.7 (5.4) 35.7 (5.2) 0.949 35.5 (4.9) 0.638
doi:10.1371/journal.pone.0164620.t001
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Table 3. Association between menstrual and reproductive characteristics and colorectal cancer risk by educational level.
COLORECTAL CANCER
Primary school or less Secondary school or University
Variablea controls cases ORb 95% CI p-val controls cases ORb 95% CI p-val P-int.c
Premenopausal status 99 27 0.86 0.51 - 1.46 0.575 357 42 0.65 0.42 - 1.01 0.054 0.360
Nulliparity 70 29 0.71 0.44 - 1.15 0.167 208 42 0.95 0.64 - 1.41 0.798 0.366
Parous women
Age at first birth (years)
<25 277 164 1.00 160 42 1.00
25–29 276 136 0.77 0.57 - 1.04 0.091 257 52 0.72 0.45 - 1.15 0.168
>29 117 57 0.75 0.51 - 1.11 0.152 229 37 0.68 0.41 - 1.13 0.138
Five-year trend* 0.97 0.83 - 1.13 0.671 0.91 0.74 - 1.11 0.353 0.629
No. of children
1–2 420 184 1.00 482 106 1.00
3–4 212 139 1.27 0.94 - 1.70 0.116 138 22 0.54 0.32 - 0.90 0.019
> 4 46 35 1.33 0.81 - 2.20 0.262 26 5 0.49 0.18 - 1.38 0.180
Trend per child* 1.10 0.99 - 1.21 0.072 0.77 0.63 - 0.94 0.012 0.001
Lactation first child (months)
None 137 65 1.12 0.77 - 1.63 0.548 104 27 1.13 0.68 - 1.88 0.646
1–6 323 134 1.00 359 75 1.00
>6 139 112 1.55 1.10 - 2.18 0.012 78 12 0.68 0.35 - 1.34 0.266
Six-month trend* 1.17 1.01 - 1.34 0.031 0.82 0.59 - 1.15 0.249 0.040
No. of miscarriages
None 584 317 1.00 647 132 1.00
One or more 165 70 0.81 0.59 - 1.13 0.212 209 43 1.09 0.74 - 1.62 0.657 0.686
Age at menarche (years)
<12 134 58 0.84 0.57 - 1.22 0.353 186 45 1.51 0.98 - 2.33 0.059
12–13 317 161 1.00 432 66 1.00
>13 289 166 0.99 0.75 - 1.32 0.972 234 61 1.57 1.06 - 2.34 0.026
Trend per year* 1.03 0.96 - 1.11 0.430 1.04 0.94 - 1.16 0.444 0.861
Hormonal contraception use
Never 475 305 1.00 334 85 1.00
Ever 274 82 0.55 0.40 - 0.75 <0.001 522 90 0.75 0.53 - 1.06 0.099 0.179
< = 5 years 105 34 0.59 0.38 - 0.92 0.019 210 41 0.82 0.53 - 1.26 0.368
>5 years 78 25 0.66 0.40 - 1.10 0.111 171 21 0.51 0.30 - 0.87 0.014
Not known 91 23 0.42 0.25 - 0.70 0.001 141 28 0.94 0.57 - 1.55 0.806
Postmenopausal women
Age at menopause (years)
< = 45 142 64 0.80 0.54 - 1.20 0.283 103 33 1.22 0.69 - 2.15 0.494
46–49 143 79 0.95 0.65 - 1.39 0.787 116 31 1.07 0.60 - 1.90 0.815
50–52 164 102 1.00 130 33 1.00
>52 138 74 0.88 0.60 - 1.30 0.528 74 20 0.91 0.48 - 1.73 0.774
Five-year trend* 1.05 0.92 - 1.21 0.465 0.87 0.71 - 1.06 0.161 0.114
Fertility time (years)
<33 137 79 1.00 99 30 1.00
33–36 162 93 1.00 0.67 - 1.48 0.992 107 35 1.04 0.58 - 1.85 0.904
37–39 144 74 0.85 0.56 - 1.28 0.428 119 28 0.74 0.40 - 1.34 0.317
>39 138 72 0.86 0.57 - 1.30 0.477 95 23 0.68 0.36 - 1.28 0.231
Five-year trend* 1.02 0.89 - 1.16 0.774 0.87 0.71 - 1.06 0.168 0.189
(Continued )
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with low and high educational level, with the interaction term proving statistically significant
(P = 0.001 and 0.040 respectively): while parity showed a positive trend among women with
low educational level (primary school or less), in women with higher level of education (sec-
ondary school or university) the OR decreased by 23% for every child (P = 0.012). With respect
to months of lactation, whereas those women with lower educational background who
breastfed their first child for longer periods registered an increased CRC risk (>6 months vs.
1–6 months: OR = 1.55; 95%CI = 1.10–2.18; P trend = 0.031), those with higher education,
showed the opposite effect, although this association was not statistically significant, probably
due to the small number of cases who breastfed more than six months. The protection con-
ferred by hormonal contraception and hormone replacement therapy use was in evidence in
both groups, although it was stronger for women with low educational level. While duration of
hormonal contraception use was not associated with CRC risk in women with low educational
level, in those with higher educational background the risk decreased by 28% for every 5-year
increase in hormonal contraception use (P = 0.032) (data not shown). Finally we also detected
a U-shape association with age at menarche among women with higher educational level (<12
years vs. 12–13: OR = 1.51; 95%CI = 0.98–2.33;>13 years vs. 12–13: OR = 1.57; 95%CI = 1.06–
2.34). These analyses were repeated additionally adjusting for the above mentioned dietary var-
iables, but this led to no change in the results (S2 Table).
Discussion
This case-control study with population controls examines the association between recalled
menstrual and reproductive factors and GC and CRC risk, and evaluates whether the effect dif-
fer by educational level. Our results show a decreasedGC risk associated with older age at first
birth; a decreasedGC, CC and RC risk associated with ever use of hormonal contraception and
a decreasedCC and RC risk among postmenopausal hormone therapy users.Women with low
educational level who had more children or who breastfed their first child for longer periods
registered an increased CRC risk, while those with higher educational background showed the
opposite effect.
One of the main strengths of this study is its large sample size, since to date it is the largest
epidemiological study that analyses the association betweenGC and CRC risk and menstrual
and reproductive factors in the Spanish population. The study was carried out in 11 Spanish
provinces, covering rural and urban areas. In addition, we have used histologically confirmed
incident cases and population-based controls. Finally, the random province-specific intercept
Table 3. (Continued)
COLORECTAL CANCER
Primary school or less Secondary school or University
Variablea controls cases ORb 95% CI p-val controls cases ORb 95% CI p-val P-int.c
Hormone therapy use
Never 585 350 1.00 440 121 1.00
Ever 65 10 0.30 0.15 - 0.60 0.001 59 12 0.74 0.38 - 1.47 0.393 0.064
a Totals do not add up because of missing values.
b Odds ratios (ORs) and 95% confidence intervals (95% CI) adjusted for age, BMI 1-year prior to the interview, family history of colorectal cancer, tobacco,
hormone therapy use and hormonal contraception use (the latter two variables were excluded as confounders when analyzing their association with
colorectal cancer risk). Province was included as a random effect term.
c P-int.: P value of the interaction term between educational level and the corresponding variable.
* In italics: ORs, 95% CI and P values obtained with the corresponding variable as a continuous term.
doi:10.1371/journal.pone.0164620.t003
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term included in our statistical models allowed us to take into account unexplained heterogene-
ity due to unmeasured factors across different provinces.
Some limitations should also be considered. First, self-reported information is subjected to
recall bias. However, if this bias exists, it would probably be non-differential, since the possible
association between reproductive factors and GC and CRC risk is largely unknown. Several
previous studies have concluded that self-reported information of age at menopause, age at
menarche, number of children, age at first pregnancy, age at first and last birth and spontane-
ous abortions are recalledwith reasonable accuracy [18, 19]. These same variables were used in
a previous study of our group that analyzed the influence of obstetric factors on mammo-
graphic density in adult Spanish women [20]. In a quality control analysis of that study, which
included re-test in a subsample of women, we showed acceptable levels of reproducibility.
Regarding a potential selection bias, we have evaluated possible differences betweenwomen
with complete and missing data in terms of demographic and other confounding variables and
we observed that women unable to provide this information were older and had lower educa-
tional background than those who did, being this difference similar in cases and controls.
Another limitation is the high number of missing values in dietary variables. However, when
we replicated the analyses introducing these variables in the models (S1 Table and S2 Table)
results were not altered. It could be possible that unmeasured confounders affect our findings.
Nevertheless, most established GC risk factors were controlled in the present study, with the
exception ofHelicobacter pylori infection.However, the infection caused by this bacterium is
not a confounding factor in our study since, in agreement with the literature, no association
was observedbetween this infection,measured by a serological assay, and the reproductive fac-
tors studied here (data not shown). Moreover, those unmeasured characteristics that could
have a geographical distribution have been at least partly accounted for through the random
effect province term included in our statistical analyses. Finally, we have small sample size to
find statistically significant associations when evaluating certain subgroup associations for GC,
such as the stratified analyses by anatomic subsite, histologic type or educational level.
Age at first birth was inversely associated with GC risk in the present study. In a previous
meta-analysis no association with this variable was detected [11]. Nevertheless, some studies of
this meta-analysis have found a borderline inverse association of age at first birth with GC in
general [21], with all subsites and histological types of GC [22], with adenocarcinomas of the
gastric cardia [23, 24], and with non-cardia gastric cancer in postmenopausal women[23].
Our results suggest a protective role of exogenous female hormones on gastric and colorectal
cancer risk. Previous studies of oral contraceptives and GC have reported risk estimates from
0.79 to 2.50, with a pooled relative risk for ever use of 1.11 [11]. Only Frise et al detected a no sig-
nificant decreased risk of gastric adenocarcinoma,more pronounced for the intestinal histologic
subtype [25]. Nevertheless, the protective effect of hormone replacement therapy on GC risk has
been reported in several studies [11, 26]. Evidence suggests that estrogens may offer protection
against the development and progression of GC by acting on ERα and ERβ. The biological path-
way is unclear, but severalmechanisms have been suggested, such as the increased expression of
trefoil factor genes, the inhibition of oncogenes’ expression or decreasing bile acid concentration
[27]. For this reason, it would be reasonable to think that parity might be associatedwith GC risk
through these pathways. However, in consonance with our findings, the most recent meta-analy-
sis of prospective cohort studies found no significant association [28].
With respect to CRC, three previous meta-analyses described an inverse association with
oral contraceptives use, with summary relative risks of 0.81 [29] and 0.82 [30, 31]. Two of them
detected no differences according to duration of use, although there were indications that the
protection was stronger for more recent use [29, 30]. Meanwhile, Luan et al described a statisti-
cally significant nonlinear inverse association with duration of use [31]. Regarding hormone
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replacement therapy, two previous meta-analyses found an approximately 20% reduction in
CRC risk among ever users [32, 33], similar for colon and rectal tumors [32]. This protective
effect seems to be modulated through the ERβ, the predominant ER in the colon. During the
tumorigenesis process, the ERβ expression in colonocytes is lost, and hormone replacement
therapy exerts its effects through preventing this loss [8]. Increased local concentration of
estrogens reduces the production of carcinogenic secondary bile acid, limits DNA damage and
microsatellite instability and inhibits cell proliferation of colonic tumors [9].
When analyzing CRC risk, we have detected an interaction betweenmonths of first birth
lactation and parity with educational level. Frise et al, in a study of reproductive factors and
risk of gastric adenocarcinoma, also detected a statistically significant interaction between
income level and parity [25]. With respect to lactation, previous studies have detected no asso-
ciation [34–36], except Lo et al, who found an inverse association with CRC risk [37]. Regard-
ing parity, Guan et al, in a meta-analysis of prospective studies, found a 5% decreasedCRC risk
among parous versus nulliparous women, although they found no dose-response effect [38]. La
Vecchia et al, in 6 out of 18 studies found significant protection by parity on CC or CRC risk
[39]. When we additionally adjusted by other dietary CRC risk factors (such as calorie intake,
red meat, processedmeat, fruits, vegetables, and alcohol consumption) we also observed a sig-
nificant interaction term with parity (P<0.001) and almost significant with duration of lacta-
tion (P = 0.051). Since we do not find a clear biologic rationale for this result, it should be
interpreted with caution in terms of prevention. It is possible that we were unable to completely
adjust for these imprecisely measured factors, which may have led to some residual confound-
ing. Other lifestyle conditions not yet identified could have influenced on these associations, as
well as early-life conditions that could not be controlled for, given that these women grew up in
a tough era marked by the Spanish civil war and long postwar period.
In brief, our results provide some support for the hypothesis that oral contraceptives and
hormone replacement therapy decrease GC and CRC risk in women.We detected a decreased
GC risk associated with advanced maternal age at first birth and a significant interaction of
educational level with parity and breastfeeding. These findings are consistent with the exoge-
nous hormone hypothesis. However, the role of endogenous hormones on GC and CRC risk
remains to be elucidated, and should be explored taking into account socioeconomic factors
and lifestyles closely related with reproductive patterns.
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